Tackling metastatic triple-negative breast cancer with sacituzumab govitecan

Figures & data

Figure 1. Depiction of sacituzumab govitecan

Figure 2. Mechanism of action of sacituzumab govitecan

Table 1. Common adverse events in 258 patients with metastatic triple-negative breast cancer receiving saituzumab govitecan and 224 patients receiving single-agent chemotherapy (eribulin, vinorelbine, capecitabine, gemcitabine) in the Phase III clinical trial. [45]

Adverse Event	Sacituzumab Govitecan		Chemotherapy
	Any Grade	Grade 3–4	Any Grade	Grade 3–4
Neutropenia	63%	51%	43%	15%
Diarrhea	59%	10%	12%	<1%
Nausea	57%	3%	26%	<1%
Alopecia^a	46%	0%	16%	0%
Fatigue	45%	3%	30%	5%
Anemia	34%	8%	24%	5%
Vomiting	29%	1%	10%	<1%
Nervous System Disorder	25%	<1%	24%	2%
Decreased Appetite	20%	2%	14%	<1%

^aThere was one patient with a grade 3 rash in both treatment groups

Table 2. Phase III results of patients treated with sacituzumab govitecan and single-agent chemotherapy (eribulin, vinorelbine, capecitabine, gemcitabine) in metastatic triple-negative breast cancer. [45]

Treatment	Number of Patients	ORR	Median PFS (Months)	Median OS (Months)
Sacituzumab Govitecan	235^a	35%	5.6 (95% CI, 4.3 to 6.3)	12.1 (95% CI, 10.7 to 14.0)
Chemotherapy	233	5%	1.7 (95% CI, 1.5 to 2.6)	6.7 (95% CI, 5.8–7.7)

^aPatients without brain metastases. ORR: objective response rate. PFS: progression-free survival. OS: overall survival, CI: confidence interval.